Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
386
Recruiting Now
386
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT04982276 Phase 1, Phase 2
Recruiting
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophagea...
Condition
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Enrollment
138 pts
Location
China
Sponsor
Akeso
NCT05615389 Phase 1, Phase 2
Recruiting
Pilot Study of MC in Paediatric Palliative Care
Condition
Palliative Care
Enrollment
10 pts
Location
Australia
Sponsor
Murdoch Childrens Research Ins
NCT06596018 Phase 1, Phase 2
Recruiting
Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemother...
Condition
Breast Adenocarcinoma
Enrollment
96 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc
NCT06712680 Phase 1, Phase 2
Recruiting
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and...
Condition
Solid Tumor
Enrollment
115 pts
Location
China
Sponsor
Sichuan Huiyu Pharmaceutical C
NCT07070323 Phase 1, Phase 2
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody...
Condition
T-Cell Acute Lymphocytic Leukemia
Enrollment
54 pts
Location
China
Sponsor
Beijing GoBroad Hospital
NCT06932523 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy ...
Condition
Herpes Zoster (HZ)
Enrollment
645 pts
Location
China
Sponsor
Shanghai Institute Of Biologic
NCT06108063 Phase 1, Phase 2
Recruiting
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
Condition
Knee Arthroplasty, Total
Enrollment
120 pts
Location
United States
Sponsor
Steadman Philippon Research In
NCT06255626 Phase 1, Phase 2
Recruiting
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vacc...
Condition
COVID-19
Enrollment
215 pts
Location
France
Sponsor
ANRS, Emerging Infectious Dise
NCT07215234 Phase 1, Phase 2
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in...
Condition
Geographic Atrophy
Enrollment
104 pts
Location
United States, Australia
Sponsor
Sanofi
NCT05525247 Phase 1, Phase 2
Recruiting
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC...
Condition
Advanced Solid Tumor
Enrollment
420 pts
Location
United States, Australia, South Korea
Sponsor
Selecxine
NCT06965114 Phase 1, Phase 2
Recruiting
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Pat...
Condition
Hairy Cell Leukemia
Enrollment
84 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05920798 Phase 1, Phase 2
Recruiting
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube,...
Condition
Fallopian Tube Carcinosarcoma
Enrollment
40 pts
Location
United States
Sponsor
Mayo Clinic
NCT05451784 Phase 1, Phase 2
Recruiting
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive ...
Condition
Metastatic Triple-Negative Breast Carcinoma
Enrollment
20 pts
Location
Spain
Sponsor
Fundacio Clinic Barcelona
NCT07439848 Phase 1, Phase 2
Recruiting
Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as A...
Condition
Acute Respiratory Distress Syndrome
Enrollment
15 pts
Location
Indonesia
Sponsor
PT. Prodia Stem Cell Indonesia
NCT07589543 Phase 1, Phase 2
Recruiting
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Condition
Epithelial Ovarian Cancer
Enrollment
42 pts
Location
China
Sponsor
Beijing Biotech
NCT07432633 Phase 1, Phase 2
Recruiting
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology In...
Condition
Colorectal Cancer
Enrollment
71 pts
Location
United States
Sponsor
Blue Earth Diagnostics
NCT05938465 Phase 1, Phase 2
Recruiting
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in ...
Condition
Ileal Pouch
Enrollment
50 pts
Location
United States
Sponsor
Exegi Pharma, LLC
NCT06827236 Phase 1, Phase 2
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called...
Condition
Locally Advanced Breast Cancer
Enrollment
380 pts
Location
United States, Canada, China
Sponsor
BioNTech SE
NCT07312864 Phase 1, Phase 2
Recruiting
Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure an...
Condition
Liver Failure
Enrollment
12 pts
Location
China
Sponsor
Beijing Friendship Hospital
NCT07241936 Phase 1, Phase 2
Recruiting
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatmen...
Condition
Advanced Solid Tumors
Enrollment
444 pts
Location
China
Sponsor
CSPC ZhongQi Pharmaceutical Te
NCT03128034 Phase 1, Phase 2
Recruiting
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-...
Condition
Acute Lymphoblastic Leukemia
Enrollment
75 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT06529809 Phase 1, Phase 2
Recruiting
Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-a...
Condition
Locally Advanced Cervical Carcinoma
Enrollment
50 pts
Location
United States
Sponsor
Washington University School o
NCT07145047 Phase 1, Phase 2
Recruiting
Clinical Study of Oncolytic Virus in Glioblastoma
Condition
Glioblastoma (GBM)
Enrollment
20 pts
Location
China
Sponsor
Mianyang Central Hospital
NCT07558733 Phase 1, Phase 2
Recruiting
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With H...
Condition
HR+ HER2- Breast Cancer
Enrollment
32 pts
Location
United States
Sponsor
Faeth Therapeutics
NCT00722228 Phase 1, Phase 2
Recruiting
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Condition
Colorectal Cancer
Enrollment
50 pts
Location
Israel
Sponsor
Hadassah Medical Organization
Page 1 of 16 — 386 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology